PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 22 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Prenylflavonoids and extracts show antibacterial activity against MRSA and Enterococcus spp. [PMID:29433688, PMID:40840729]
Sanggenol L prevented brain injury and reduced infarct volume in rat models [PMID:40542887]
Methanolic extract (MEMARB) reduced serum amylase, lipase, and inflammatory markers in rat models [PMID:30335608, PMID:30302330]
High-dose alcohol extract (600 mg/kg) significantly reduced glucose and increased insulin levels in STZ-induced diabetic rats [PMID:15885940]
Water extracts alleviated osteoarthritis symptoms and prevented reduction of bone mineral density in testosterone-deficient rats [PMID:33371279]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 40840729 (2025) — Sanggenon C - A novel anti-enterococcal agent from Morus alba root bark. · Journal of ethnopharmacology
- 2.PMID: 40542887 (2025) — Sanggenol L inhibits the HMGB1/TLR4/NF-κB signaling pathway to prevent cerebral ischemia-reperfusion damage. · Journal of molecular histology
- 3.PMID: 39252692 (2024) — Biopharmaceutical profiling of anti-infective sanggenons from Morus alba root bark for inhalation administration. · International journal of pharmaceutics: X
- 4.PMID: 29433688 (2018) — Synergism of prenylflavonoids from Morus alba root bark against clinical MRSA isolates. · Phytomedicine : international journal of phytotherapy and phytopharmacology
- 5.PMID: 31610262 (2020)